Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
Open Access
- 27 November 2020
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 8 (12), 1885
- https://doi.org/10.3390/microorganisms8121885
Abstract
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14–104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years (p < 0.001) and need for hospitalization (p < 0.001) correlated with higher antibody titers, while asymptomatic status (p < 0.001) and testing >60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers.This publication has 34 references indexed in Scilit:
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Hematological findings and complications of COVID‐19American Journal of Hematology, 2020
- Humoral Immune Responses in COVID-19 Patients: A Window on the State of the ArtFrontiers in Immunology, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences of the United States of America, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic MechanismsACS Chemical Neuroscience, 2020
- Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccinesGenome Medicine, 2018
- Persistence of Antibodies against Middle East Respiratory Syndrome CoronavirusEmerging Infectious Diseases, 2016
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryThe New England Journal of Medicine, 2007